Handelsavisen
prelaunch
Companies Healthcare V3VN.DE
V3
V3VN.DE XETRA Healthcare Facilities & Services

FamiCord AG

Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-11,3 %
ROE
-85,9 %
Net margin
-14,8 %
Debt / equity
1,28
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

V3VN.DE operates in the healthcare sector, focusing on biotechnology and healthcare facilities and services.

Business. V3VN.DE is a biotechnology company operating within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models and is listed on the Xetra exchange. Specific details regarding its operating segments, headquarters location, and geographic presence are not available in the provided data. Consequently, the company is described at the industry level without further operational breakdown.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
HOLD1 analysts
0 buy1 hold0 sell
Avg 12m price target7,50

Analyst recommendations

1 analysts · consensus Hold
Buy0
Hold1
Sell0
12-month price target
7,50
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
1 analysts · indicative
Ownership
not yet wired
Profitability
-85,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning V3VN.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to V3VN.DE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    V3VN.DE is a biotechnology company operating within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models and is listed on the Xetra exchange. Specific details regarding its operating segments, headquarters location, and geographic presence are not available in the provided data. Consequently, the company is described at the industry level without further operational breakdown.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 1.28, indicating a relatively high level of leverage. Despite having cash and equivalents of 16,823,000 EUR, the company's liquidity is assessed as medium, and its free cash flow is negative at -6,825,000 EUR, suggesting cash flow constraints. The company's return on equity is -0.8586, and its return on assets is -0.0795, both of which are negative and indicate poor profitability relative to its equity and asset base.

    The company's profitability is weak, with an operating loss of 9,258,000 EUR and a net loss of 12,136,000 EUR. These figures are below the industry median for profitability metrics, indicating that the company is underperforming its peers in terms of generating profit. The company's gross profit of 29,352,000 EUR is also below the industry median, suggesting that it is not as efficient in converting revenue into profit as its competitors.

    The company's revenue is concentrated in a single segment, as no additional segments are disclosed. The geographic exposure is not specified, but the company's operations are likely centered in its home market. The lack of segment and geographic diversification increases the company's exposure to market-specific risks.

    The company's growth trajectory is uncertain, as there are no specific numeric deltas provided for the current or next fiscal year. The company's operating cash flow of 8,655,000 EUR is positive, but the free cash flow is negative, indicating that the company is not generating enough cash to fund its operations and capital expenditures. The company's capital expenditure of -3,199,000 EUR suggests that it is investing in its operations, but the negative free cash flow indicates that these investments are not being funded by operating cash flow.

    The company's risk factors include medium liquidity risk and low dilution potential. The key flag of net cash being negative after subtracting total debt indicates that the company's cash position is not sufficient to cover its debt obligations. The company's dilution potential is low, suggesting that there is little risk of share dilution in the near term.

    Recent events include analyst estimates that suggest a mean price target of 7.50 EUR, with a mean recommendation of 3.00, indicating a hold rating. There are no strong buy or buy recommendations, and only one hold recommendation, suggesting that analysts are cautious about the company's prospects.

    Key takeaways
    • The company has a high debt-to-equity ratio of 1.28, indicating a leveraged capital structure.
    • The company's profitability is weak, with a negative return on equity and return on assets.
    • The company's free cash flow is negative, indicating cash flow constraints.
    • The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year.
    • The company's liquidity risk is medium, and its dilution potential is low.
    • margin_outlook_rationale: The company's margin outlook is negative due to its weak profitability and high operating costs.
    • rd_outlook_rationale: The company's R&D outlook is uncertain, as there is no specific information provided on R&D expenditures or projects.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    €14.1M
    Net cash
    -€1.3M
    Current ratio
    0.7
    Debt / equity
    1.3
    ROA
    -8.0%
    ROE
    -85.9%
    Cash conversion
    -71.0%
    CapEx / revenue
    -3.9%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low€7,50
    Mean€7,50
    Median€7,50
    High€7,50
    Spot
    12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-11,3 %Bottom quartile
    Net Margin-14,8 %Bottom quartile
    ROE-85,9 %Bottom quartile
    Capex / Rev-3,9 %Above median
    D/E1,28Bottom quartile
    Cash Conv-0,71Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • V3VN.DE Market data — financials · 2026-05-29
    • FamiCord AG Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    V3VN.DECanonical
    XETRA · EUR

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage